The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Temodal temozolomide | Merck Sharp & Dohme B.V. | Glioma | 🇪🇺 EU 1999-01-26 | Order → |
| Forcaltonin recombinant salmon calcitonin | Unigene UK Ltd. | Hypercalcemia; Osteitis Deformans; Bone Resorption | 🇪🇺 EU 1999-01-11 | Order → |
| Triacelluvax diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed) | Chiron S.p.A. | Immunization; Tetanus; Whooping Cough; Diphtheria | 🇪🇺 EU 1999-01-11 | Order → |
| Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) telmisartan | Bayer AG | Hypertension | 🇪🇺 EU 1998-12-16 | Order → |
| Micardis telmisartan | Boehringer Ingelheim International GmbH | Hypertension | 🇪🇺 EU 1998-12-16 | Order → |
| Pritor telmisartan | Bayer AG | Hypertension | 🇪🇺 EU 1998-12-11 | Order → |
| Prometax rivastigmine | Almirall, S.A. | Alzheimer Disease; Parkinson Disease; Dementia | 🇪🇺 EU 1998-12-04 | Order → |
| Karvezide irbesartan;hydrochlorothiazide | Sanofi Winthrop Industrie | Hypertension | 🇪🇺 EU 1998-10-16 | Order → |
| CoAprovel irbesartan;hydrochlorothiazide | Sanofi Winthrop Industrie | Hypertension | 🇪🇺 EU 1998-10-14 | Order → |
| Simulect basiliximab | Novartis Europharm Limited | Graft Rejection; Kidney Transplantation | 🇪🇺 EU 1998-10-09 | Order → |
| HumaSPECT votumumab | KS Biomedix Limited | Ultrasonography; Colorectal Neoplasms; Tomography, X-Ray Computed | 🇪🇺 EU 1998-09-25 | Order → |
| Comtan entacapone | Orion Corporation | Parkinson Disease | 🇪🇺 EU 1998-09-22 | Order → |
| Aldara imiquimod | Viatris Healthcare Limited | Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell | 🇪🇺 EU 1998-09-18 | Order → |
| Zartra imiquimod | Laboratoires 3M Santé | Condylomata Acuminata | 🇪🇺 EU 1998-09-18 | Order → |
| Comtess entacapone | Orion Corporation | Parkinson Disease | 🇪🇺 EU 1998-09-16 | Order → |
| Patrex sildenafil | Pfizer Limited | Erectile Dysfunction | 🇪🇺 EU 1998-09-15 | Order → |
| Viagra sildenafil | Viatris EESV | Erectile Dysfunction | 🇪🇺 EU 1998-09-13 | Order → |
| Fortovase saquinavir | Roche Registration Ltd. | HIV Infections | 🇪🇺 EU 1998-08-20 | Order → |
| NovoNorm repaglinide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 1998-08-16 | Order → |
| Evista raloxifene | Substipharm | Osteoporosis, Postmenopausal | 🇪🇺 EU 1998-08-05 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.